Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Table 2 Patients reporting mild, moderate or severe treatment-related adverse events during treatment with lanreotide autogel

Organ system	Severe	Moderate	Mild	Total
Any	1 (3.3)	8 (26.7)	17 (56.7)	19 (63.3)
Gastrointestinal	1 (3.3)	4 (13.3)	12 (40.0)	13 (43.3)
General and	0	5 (16.7)	9 (30.0)	10 (33.3)
injection site	0	5 (16.7)	9 (30.0)	10 (33.3)
Neurological	0	0	3 (10.0)	3 (10.0)
Metabolic and nutritional	0	1 (3.3)	1 (3.3)	2 (6.7)
Infections	0	1 (3.3)	0	1 (3.3)
Skin and subcutaneous tissue	0	0	1 (3.3)	1 (3.3)
Ear and labyrinth	0	0	1 (3.3)	1 (3.3)
Renal/urinary tract	0	1 (3.3)^a	0	1 (3.3)
Reproductive system and breast	0	0	1 (3.3)	1 (3.3)
Vascular	0	0	1 (3.3)	1 (3.3)